Ozlem Temiz-Arpaci

Ozlem Temiz-Arpaci

Auto-generated profile, based on publicly available information

Ozlem Temiz-Arpaci

Ankara University

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
EOEmine Oksuzoglu
Emine Oksuzoglu
BTBetul Tekiner-Gulbas
Betul Tekiner-Gulbas
SASabiha Alper
Sabiha Alper
OTOzlem Temiz-Arpaci
Ozlem Temiz-Arpaci
TETugba Ertan
Tugba Ertan
IYIsmail Yalcin
Ismail Yalcin
Some novel fused heterocyclic compounds of 2, 5-disubstituted-benzoxazole and benzimidazole derivatives, which were previously synthesized by our group, were investigated for their inhibitory activity on both eukaryotic DNA topoisomerase I and II in a cell free system. 2-Phenoxymethylbenzimidazole (17), 5-amino-2-(p-fluorophenyl)benzoxazole (3), 5-amino-2-(p-bromophenyl)benzoxazole (5), 5-nitro-2-phenoxymethyl-benzimidazole (18), 2-(p-chlorobenzyl)benzoxazole (10) and 5-amino-2-phenylbenzoxazole (2) were found to be more potent as eukaryotic DNA topoisomerase I poisons than the reference drug camptothecin having IC50 values of 14.1, 132.3, 134.1, 248, 443.5, and 495 μM, respectively. 5-Chloro-2-(p-methylphenyl)benzoxazole (4), 2-(p-nitrobenzyl)benzoxazole (6) and 5-nitro-2-(p-nitrobenzyl)benzoxazole (8) exhibited significant activity as eukaryotic DNA topoisomerase II inhibitors, having IC50 values of 22.3, 17.4, 91.41 μM, respectively, showing higher potency than the reference drug etoposide.

1 April 2004 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
APAsli Pinar
Asli Pinar
PYPinar Yurdakul
Pinar Yurdakul
Ilkay YildizIlkay Yildiz
Ilkay Yildiz
OTOzlem Temiz-Arpaci
Ozlem Temiz-Arpaci
NAN.LEyla Acan
N.LEyla Acan
IYIsmail Yalcin
Ismail Yalcin

1 February 2009 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TETugba Ertan
Tugba Ertan
Ilkay YildizIlkay Yildiz
Ilkay Yildiz
BTBetul Tekiner-Gulbas
Betul Tekiner-Gulbas
KBKayhan Bolelli
Kayhan Bolelli
OTOzlem Temiz-Arpaci
Ozlem Temiz-Arpaci
EAEsin Aki
Esin Aki

1 November 2008 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SASabiha Alper-Hayta
Sabiha Alper-Hayta
MAMustafa Arisoy
Mustafa Arisoy
ÖTÖzlem Temiz-Arpaci
Özlem Temiz-Arpaci
Ilkay YildizIlkay Yildiz
Ilkay Yildiz
EAEsin Aki
Esin Aki
FKFatma Kaynak
Fatma Kaynak

1 October 2012 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
YMY. Sheena Mary
Y. Sheena Mary
KRK. Raju
K. Raju
Ilkay YildizIlkay Yildiz
Ilkay Yildiz
OTOzlem Temiz-Arpaci
Ozlem Temiz-Arpaci
Helena  NogueiraHelena Nogueira
Helena Nogueira
CAChristian Van Alsenoy
Christian Van Alsenoy

31 March 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
RPRichard K. Plemper
Richard K. Plemper
KEKarl J. Erlandson
Karl J. Erlandson
ALAmi S. Lakdawala
Ami S. Lakdawala
ASAiming Sun
Aiming Sun
Andrew PrussiaAndrew Prussia
Andrew Prussia
RCRichard W. Compans
Richard W. Compans
Measles virus (MV) constitutes a principal cause of worldwide mortality, accounting for almost 1 million deaths annually. Although a live-attenuated vaccine protects against MV, vaccination efficiency of young infants is low because of interference by maternal antibodies. Parental concerns about vaccination safety further contribute to waning herd immunity in developed countries, resulting in recent MV outbreaks. The development of novel antivirals that close the vaccination gap in infants and silence viral outbreaks is thus highly desirable. We previously identified a microdomain in the MV fusion protein (F protein) that is structurally conserved in the paramyxovirus family and constitutes a promising target site for rationally designed antivirals. Here we report the template-based development of a small-molecule MV inhibitor, providing proof-of-concept for our approach. This lead compound specifically inhibits fusion and spread of live MV and MV glycoprotein-induced membrane fusion. The inhibitor induces negligible cytotoxicity and does not interfere with receptor binding or F protein biosynthesis or transport but prevents F protein-induced lipid mixing. Mutations in the postulated target site alter viral sensitivity to inhibition.In silicodocking of the compound in this microdomain suggests a binding model that is experimentally corroborated by a structure-activity analysis of the compound and the inhibition profile of mutated F proteins. A second-generation compound designed on the basis of the interaction model shows a 200-fold increase in antiviral activity, creating the basis for novel MV therapeutics. This template-based design approach for MV may be applicable to other clinically relevant members of the paramyxovirus family.